SBE-β-CD

CAS No. 182410-00-0

SBE-β-CD( Sulfobutylether-β-Cyclodextrin )

Catalog No. M22582 CAS No. 182410-00-0

SBE-β-CD is a sulfobutylether β-cyclodextrin derivative with a sodium sulfonate salt separated from the lipophilic cavity by a butyl ether spacer group, or sulfobutylether (SBE).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
500MG 37 In Stock
1G 59 In Stock

Biological Information

  • Product Name
    SBE-β-CD
  • Note
    Research use only, not for human use.
  • Brief Description
    SBE-β-CD is a sulfobutylether β-cyclodextrin derivative with a sodium sulfonate salt separated from the lipophilic cavity by a butyl ether spacer group, or sulfobutylether (SBE).
  • Description
    SBE-β-CD is a sulfobutylether β-cyclodextrin derivative with a sodium sulfonate salt separated from the lipophilic cavity by a butyl ether spacer group, or sulfobutylether (SBE).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Sulfobutylether-β-Cyclodextrin
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    182410-00-0
  • Formula Weight
    ——
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:5.625 mg/mL(Need ultrasonic and warming); H2O:250 mg/mL:Need ultrasonic
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Fukuda M, et al.Influence of sulfobutyl ether beta-cyclodextrin (Captisol) on the dissolution properties of a poorly soluble drug from extrudates prepared by hot-melt extrusion.Int J Pharm. 2008 Feb 28;350(1-2):188-196
molnova catalog
related products
  • Vardenafil Dihydroch...

    Vardenafil Dihydrochloride Salt is a phosphodiesterase inhibitor that is selective for PDE5 and PDE1 (IC50 = 0.7 and 180 nM, respectively).

  • Dynorphin A (2-12), ...

    Dynorphin A (2-12), porcine

  • Fluorofenidone

    Fluorofenidone attenuates the progression of renal interstitial fibrosis partly by suppressing NADPH oxidase and extracellular matrix (ECM) deposition via the PI3K/Akt signalling pathway.